Work

Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1

Year: 2020

Type: article

Abstract: At week 64, 72.1% (n = 44), 31.1% (n = 19), and 13.1% (n = 8) of the patients who were retreated after relapse achieved PASI 75, PASI 90, and PASI 100 responses, respectively (Figure 2)

Source: SKIN The Journal of Cutaneous Medicine

DOI: 10.25251/skin.4.supp.40

Authors: Wendy Cantrell, Patricia Lee, Alan M Mendelsohn, Jeff Parno, Stephen J Rozzo, Wilson Liao

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3086770384

FWCI: 0.087

Cites:

Cited by: 1

Related to: 10